143 results on '"Oosterveer, Maaike H."'
Search Results
2. Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in Aldob deficiency
3. Genetic deletion of hepatic NCOR1 protects from atherosclerosis by promoting alternative bile acid-metabolism and sterol excretion
4. Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia
5. Characterization of milk oligosaccharide and sialic acid content and their influence on brain sialic acid in a lean mouse model for gestational diabetes
6. High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia
7. Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia
8. Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose
9. Hyperglycemia, pregnancy outcomes and maternal metabolic disease risk during pregnancy and lactation in a lean gestational diabetes mouse model
10. Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia
11. Hyperglycaemia, pregnancy outcomes and maternal metabolic disease risk during pregnancy and lactation in a lean gestational diabetes mouse model
12. Identification of the fructose transporter GLUT5 (SLC2A5) as a novel target of nuclear receptor LXR
13. Additional file 1 of Genetic deletion of hepatic NCOR1 protects from atherosclerosis by promoting alternative bile acid-metabolism and sterol excretion
14. Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease
15. SUMOylation-Dependent LRH-1/PROX1 Interaction Promotes Atherosclerosis by Decreasing Hepatic Reverse Cholesterol Transport
16. A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets
17. Dynamic Methods for Childhood Hypoglycemia Phenotyping: A Narrative Review
18. Increased atherosclerosis in a mouse model of glycogen storage disease type 1a
19. The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity
20. Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9–Mediated Gene Editing
21. TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading
22. Hepatic glucose sensing and integrative pathways in the liver
23. Short-Chain Fatty Acids Protect Against High-Fat Diet–Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation
24. Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9–Mediated Gene Editing
25. LRH-1-dependent glucose sensing determines intermediary metabolism in liver
26. Hepatic ChREBP activation limits NAFLD development in a mouse model for Glycogen Storage Disease type Ia
27. Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPAR gamma signature
28. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels
29. Fish Oil Does Not Prevent High Fat Diet-Induced Peripheral Insulin Resistance in Mice: 1258-P
30. Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPARγ signature
31. Resistance to diet-induced adiposity in cannabinoid receptor-1 deficient mice is not due to impaired adipocyte function
32. Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPARγ signature.
33. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels.
34. Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice
35. Hepatocytes Contribute to Residual Glucose Production in a Mouse Model for Glycogen Storage Disease Type Ia
36. Mechanisms by Which Metabolic Reprogramming in GSD1 Liver Generates a Favorable Tumorigenic Environment
37. LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer
38. Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice.
39. A Computational Model for the Analysis of Lipoprotein Distributions in the Mouse: Translating FPLC Profiles to Lipoprotein Metabolism
40. Hepatic glucose sensing and integrative pathways in the liver
41. Resistance to diet-induced adiposity in cannabinoid receptor-1 deficient mice is not due to impaired adipocyte function
42. Parameter Trajectory Analysis to Identify Treatment Effects of Pharmacological Interventions
43. LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer.
44. Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice
45. High Fat Feeding Induces Hepatic Fatty Acid Elongation in Mice
46. An Increased Flux through the Glucose 6-Phosphate Pool in Enterocytes Delays Glucose Absorption in Fxr–/– Mice
47. Lxrα Deficiency Hampers the Hepatic Adaptive Response to Fasting in Mice
48. The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity.
49. Fish Oil Does Not Prevent High Fat Diet-Induced Peripheral Insulin Resistance in Mice.
50. Hepatic Glucose-6-Phosphate Metabolism Is Perturbed in LXR-Alpha Null Mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.